スマンクス/リピオドール動注療法の個別化対応と注意点 : 肝腫瘍血管の異常とその他の臓器腫瘍別投与に対する考察  [in Japanese] Personalized targeting cancer chemotherapy with SMANCS/lipiodol and the points of this therapy.:Personalized targeting cancer chemotherapy with SMANCS/lipiodol and the points of this therapy  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

スマンクス/リピオドール動注療法が肝細胞癌の治療に用いられるようになり, 約20年が経過した<SUP>1,2)</SUP>. スマンクス/リピオドールの性質, あるいは動注化学療法の特徴を再確認することにより, 個々の患者の個別性に対応し, かつ, さらなるスマンクス/リピオドールの治療効果があげられると考えられる. 本論文では筆者らが, これまで20年近く行ってきたスマンクス/リピオドール動注療法の経験を踏まえて紹介するとともに, その他の各種固型悪性腫瘍に対する固有の問題点などについて述べたい.

Targeting cancer chemotherapy with SMANCS/Lipiodol for hepatocellular carcinoma has been used for more than 20 years. We believe it is important to reconfirm the characteristics of SMANCS/Lipiodol, and refine the method of administration and management of adverse effects in order to achieve satisfactory outcome. In this report, we reveal some clinical cases not only HCC but also other malignant solid tumors through our experience of 20 years. We experienced great many patients who received the arterially targeted cancer chemotherapy with SMANCS/Lipiodol for 20 years, so we would like to introduce various cases of different kinds of cancers and organic features when we perform arterial administration of SMANCS/Lipiodol.

Journal

  • Drug Delivery System

    Drug Delivery System 17(2), 94-102, 2002-03-10

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References:  13

Cited by:  2

Codes

  • NII Article ID (NAID)
    10008132169
  • NII NACSIS-CAT ID (NCID)
    AN10084591
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • ISSN
    09135006
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top